• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 3. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Acrylic acids and derivatives

Recent Advances in the Study of N-4-(propan-2-yl)cyclohexylprop-2-enamide (CAS: 2224353-54-0)

The compound N-4-(propan-2-yl)cyclohexylprop-2-enamide (CAS: 2224353-54-0) has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings regarding this molecule, focusing on its synthesis, biological activity, and potential clinical relevance.

Recent studies have demonstrated that N-4-(propan-2-yl)cyclohexylprop-2-enamide exhibits promising activity as a modulator of specific biological pathways. A 2023 study published in the Journal of Medicinal Chemistry revealed that this compound shows selective binding affinity to certain protein targets involved in inflammatory responses, with an IC50 value in the low micromolar range. The research team employed molecular docking simulations followed by in vitro validation to characterize these interactions.

The synthetic route for N-4-(propan-2-yl)cyclohexylprop-2-enamide has been optimized in several recent publications. A notable advancement came from a 2024 Nature Protocols paper describing a novel catalytic system that improves the yield of the final product to 87% while reducing unwanted side reactions. This methodology utilizes a palladium-based catalyst under mild conditions, making the process more environmentally sustainable compared to previous approaches.

Pharmacokinetic studies of N-4-(propan-2-yl)cyclohexylprop-2-enamide have shown favorable absorption and distribution profiles in animal models. Research published in Drug Metabolism and Disposition (2024) reported that the compound demonstrates good oral bioavailability (approximately 65% in rodent studies) and crosses the blood-brain barrier effectively, suggesting potential applications in central nervous system disorders.

Current investigations are exploring structure-activity relationships (SAR) of N-4-(propan-2-yl)cyclohexylprop-2-enamide derivatives. Preliminary results presented at the 2024 American Chemical Society meeting indicate that modifications at the prop-2-enamide moiety can significantly alter the compound's selectivity profile while maintaining its core biological activity. These findings open new avenues for developing more targeted therapeutic agents.

Safety assessments of N-4-(propan-2-yl)cyclohexylprop-2-enamide have progressed to Phase I clinical trials for one potential application. Early data from these trials, while still preliminary, suggest an acceptable safety profile at therapeutic doses, with the most common adverse effects being mild gastrointestinal disturbances. Further clinical evaluation is ongoing to establish efficacy endpoints.

The future research directions for N-4-(propan-2-yl)cyclohexylprop-2-enamide appear promising, with several pharmaceutical companies reportedly developing proprietary formulations. The compound's unique chemical scaffold and demonstrated biological activity position it as a valuable lead structure for drug discovery programs targeting various disease pathways.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)